In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Orexin (hypocretin) neuropeptides regulate arousal and sleep.
• Antagonizing orexin signaling promotes sleep and is a therapeutic target for insomnia disorder.

Purpose of the Study:

• To characterize lemborexant, a novel dual orexin receptor antagonist (DORA).
• To evaluate lemborexant as a potential treatment for insomnia disorder.
• To compare lemborexant's properties with other DORAs, almorexant and suvorexant.

Main Methods:

• In vitro and in silico preclinical pharmacological characterization.
• Orexin receptor binding and functional inhibition assays.
• Selectivity profiling against 88 other receptors, transporters, and ion channels.
• In silico modeling of lemborexant within orexin receptors.

Main Results:

• Lemborexant competitively inhibits both orexin receptors with low nanomolar potency.
• No species differences were observed in receptor binding (human, rat, mouse).
• Lemborexant exhibits rapid binding and dissociation kinetics.
• High selectivity for orexin receptors over 88 other targets.
• In silico modeling revealed a conserved binding conformation similar to suvorexant.

Conclusions:

• Lemborexant is a potent and selective DORA with favorable preclinical pharmacological properties.
• Its mechanism of action targets the orexin pathway, offering a novel approach for insomnia treatment.
• Lemborexant demonstrates potential as an effective therapeutic agent for managing excessive wakefulness in insomnia disorder.